Chapter 74

Cystic Tumors Other than IPMN

When to Observe, When to Operate, and Optimal Surgical Approach

John W. Kunstman

John W. Kunstman

Department of Surgery, Section of Surgical Oncology, Yale University School of Medicine, New Haven, CT, USA

VA Connecticut Health System, Department of Veterans Affairs, West Haven, CT, USA

Search for more papers by this author
James J. Farrell

James J. Farrell

Yale Pancreatic Disease Program, Interventional Endoscopy and Pancreatic Disease, Yale University School of Medicine, New Haven, CT, USA

Search for more papers by this author
First published: 16 April 2021

Summary

Management of cystic lesions of the pancreas can represent one of the most vexing clinical issues faced by the pancreatic specialist. The natural history of these lesions can range from wholly benign to overt malignancy, further increasing the anxiety of both practitioner and patient. This chapter addresses these dilemmas and presents a framework for successful management of these neoplastic cystic lesions. The most common premalignant cystic lesion of the pancreas is intraductal papillary mucinous neoplasm (IPMN). The chapter focuses on cystic neoplasms of the pancreas other than IPMN, such as mucinous cystic neoplasm (MCN), serous cystadenoma, cystic pancreatic endocrine neoplasms, solid pseudopapillary neoplasm, and other less common lesions. Longitudinal series demonstrate that only a minority of cystic lesions ultimately undergo surgical intervention. MCNs are one of two frequently encountered mucin-containing lesions of the pancreas, the other being IPMN.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.